Branded Oncology Products

Product Details:

• Fulvenat an anti-estrogen drug, is prescribed for the treatment of estrogen-related breast cancers. The drug inhibits the action of estrogen and prevents the growth of estrogen-dependent cancer cells. Fulvestrant is also prescribed in postmenopausal women with drug-resistant breast cancer.

• not previously treated with endocrine therapy, or- with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.
• In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
• In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist.

Product Details:

• Paclitax NAB monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.
• Paclitax NAB in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
• Paclitax NAB in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

Product Details:

• Nimotuzumab is a monoclonal antibody and an endothelial growth factor receptor (EGRF) antagonist.
• It also stimulates the immune system against the cancer cells.
• It is a targeted therapy used for the treatment of glioma (cancer in the brain and spinal cord), cancer of the head and neck, and nasopharyngeal cancer.
• It prevents the growth and spread of the cancer.

Product Details:

• As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.
• In combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.
• In combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
• In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.

• Hertraz is indicated for the treatment of adult patients with HER2 positive early breast cancer. (EBC).
• Following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).
• Following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.
• In combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.
• In combination with neoadjuvant chemotherapy followed by adjuvant Hertraz therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.
• Hertraz should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

• Hertraz in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
• Hertraz should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.

Product Details:

• The treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
• The treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
• The treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Product Details:

• Sorafenib is used to treat kidney, liver, and thyroid cancer. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

• Nexavar is indicated for the treatment of hepatocellular carcinoma.

• Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

• Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

Product Details:

• Sorafenib is used to treat kidney, liver, and thyroid cancer. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

• Sorafenib is indicated for the treatment of hepatocellular carcinoma.

• Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

• Sorafenib is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

Product Details:

• Erlotinib is Non-Small-Cell Lung Cancer (NSCLC). Erlotinib is indicated as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.

Product Details:

• Pemetrexed in combination with Cisplatin is indicated for the treatment of chemotherapy-naive patients with unresectable malignant pleural mesothelioma. Pemetrexed in combination with Cisplatin is indicated as a first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed is indicated as a monotherapy for the maintenance treatment of locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based therapy.

Product Details:

• Filgrastim injection is used to treat neutropenia (low white blood cells) that is caused by cancer medicines. It is a synthetic (man-made) form of a substance that is naturally produced in your body called a colony stimulating factor. Filgrastim helps the bone marrow to make new white blood cells.
• When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Filgrastim is used to prevent or reduce the risk of infection while you are being treated with cancer medicines. This medicine is also used to help the bone marrow recover after a bone marrow transplantation, for a process called peripheral blood progenitor cell collection in cancer patients, and to improve survival in cancer patients who have been exposed to radiation.